Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James E Signorovitch

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Current Medical Research and Opinion|December 17, 2013
Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record reviewMichael K Wong, Hongbo Yang, James E Signorovitch, et al.
Current Medical Research and Opinion|July 2, 2014
Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practicesEric Jonasch, James E Signorovitch, Peggy L Lin, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 25, 2012
Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness researchJames E Signorovitch, Vanja Sikirica, M Haim Erder, et al.
Journal of the American Academy of Dermatology|October 11, 2017
Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trialsKenneth B Gordon, Keith A Betts, Murali Sundaram, et al.
Journal of Medical Economics|December 15, 2015
Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the USSumanta K Pal, Eric Jonasch, James E Signorovitch, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|March 3, 2017
Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USASumanta K Pal, James E Signorovitch, Nanxin Li, et al.
Journal of Medical Economics|April 28, 2012
Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneityM Haim Erder, James E Signorovitch, Juliana Setyawan, et al.
Current Medical Research and Opinion|May 15, 2015
Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the USJipan Xie, Yanni Hao, Nanxin Li, et al.
Pharmacoeconomics|September 14, 2010
Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanerceptJames E Signorovitch, Eric Q Wu, Andrew P Yu, et al.
International Journal of Chronic Obstructive Pulmonary Disease|February 9, 2017
Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysisJames F Donohue, Keith A Betts, Ella Xiaoyan Du, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Current Medical Research and Opinion|December 17, 2013
Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record reviewMichael K Wong, Hongbo Yang, James E Signorovitch, et al.
Current Medical Research and Opinion|July 2, 2014
Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practicesEric Jonasch, James E Signorovitch, Peggy L Lin, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 25, 2012
Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness researchJames E Signorovitch, Vanja Sikirica, M Haim Erder, et al.
Journal of the American Academy of Dermatology|October 11, 2017
Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trialsKenneth B Gordon, Keith A Betts, Murali Sundaram, et al.
Journal of Medical Economics|December 15, 2015
Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the USSumanta K Pal, Eric Jonasch, James E Signorovitch, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|March 3, 2017
Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USASumanta K Pal, James E Signorovitch, Nanxin Li, et al.
Journal of Medical Economics|April 28, 2012
Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneityM Haim Erder, James E Signorovitch, Juliana Setyawan, et al.
Current Medical Research and Opinion|May 15, 2015
Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the USJipan Xie, Yanni Hao, Nanxin Li, et al.
Pharmacoeconomics|September 14, 2010
Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanerceptJames E Signorovitch, Eric Q Wu, Andrew P Yu, et al.
International Journal of Chronic Obstructive Pulmonary Disease|February 9, 2017
Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysisJames F Donohue, Keith A Betts, Ella Xiaoyan Du, et al.
Pageof 5